Nuclear medicine and biology最新文献

{"title":"Application of [99mTc]Tc-GSA in the diagnosis of Staphylococcus aureus infections","authors":"Asuka Mizutani ,&nbsp;Ami Kondo ,&nbsp;Yuka Muranaka ,&nbsp;Yuma Momose ,&nbsp;Yuri Nishiyama ,&nbsp;Kakeru Sato ,&nbsp;Masato Kobayashi ,&nbsp;Keiichi Kawai","doi":"10.1016/j.nucmedbio.2025.109021","DOIUrl":"10.1016/j.nucmedbio.2025.109021","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Staphylococcus aureus</em> can cause a variety of conditions such as bacteremia, sepsis, toxic shock syndrome, pneumonia, and infective endocarditis; therefore, a rapid and accurate diagnosis should be made to pinpoint the site of infection. This study aimed to use the existing nuclear medicine tracer [^99mTc]Tc-dimercaptosuccinic acid galactosyl human serum albumin ([^99mTc]Tc-GSA) as a simple technique for the early diagnosis of <em>S. aureus</em> infection.</div></div><div><h3>Methods</h3><div>The <em>in vitro</em> studies evaluated the accumulation of [^99mTc]Tc-GSA in <em>S. aureus</em>. In addition, the effect of metabolic and vital activity and inhibition of asialoglycoprotein receptors on [^99mTc]Tc-GSA accumulation were evaluated. <em>In vivo</em> studies were performed on the biodistribution and imaging of [^99mTc]Tc-GSA in the <em>S. aureus</em> SR3637 mouse thigh infection model.</div></div><div><h3>Results</h3><div><em>In vitro</em> studies have confirmed that [^99mTc]Tc-GSA accumulates to the same extent as 2-deoxy-2-[¹⁸F]fluoro-<span>d</span>-glucose, and it was thought that [^99mTc]Tc-GSA binds to the receptors that recognize the saccharide molecules and glycan chains expressed in <em>S. aureus</em>. In addition, in the distribution and imaging of [^99mTc]Tc-GSA, it was confirmed that the latter accumulates at the infection site and shows a clear contrast with the non-infected site.</div></div><div><h3>Conclusion</h3><div>The application of [^99mTc]Tc-GSA to the imaging diagnosis of <em>S. aureus</em> infection is expected to non-invasively detect the localization of <em>S. aureus</em> in real time, pinpoint the site of infection and determine the number of viable bacteria, and help in the selection of optimal therapeutic agents and treatments.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109021"},"PeriodicalIF":3.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel dibutyl ether resin for the purification of the Auger emitter antimony-119 from tin targets","authors":"Aivija Grundmane ,&nbsp;Caterina F. Ramogida ,&nbsp;Valery Radchenko","doi":"10.1016/j.nucmedbio.2025.109022","DOIUrl":"10.1016/j.nucmedbio.2025.109022","url":null,"abstract":"<div><div>Antimony-119 (¹¹⁹Sb, t_1/2 = 38.19 h) is an Auger electron emitting radionuclide of interest for radiopharmaceutical therapy (RPT). The potential of ¹¹⁹Sb has only been explored theoretically, due to the absence of a suitable bifunctional chelator that enables the attachment of the radionuclide onto a radiopharmaceutical. Meanwhile, potential chelators are difficult to evaluate given that the production and radiochemical purification of ¹¹⁹Sb has not been optimized for radiopharmaceutical applications. ¹¹⁹Sb can be produced from proton bombardment of tin-119 (¹¹⁹Sn) targets on medical cyclotrons, subsequently the nanograms of radioantimony must be efficiently separated from the macroscopic (&gt; mg) amount of target material while being recovered in a matrix suitable for chelation. To this end, a solid phase extraction (SPE) method employing a novel dibutyl ether (DBE) resin was developed to separate radioantimony from tin targets. The DBE resin was synthesized and characterized using thermogravimetric analysis, total organic carbon, and ¹H nuclear magnetic resonance spectroscopy. The DBE resin exhibited excellent capacity (&gt;8 mg Sb per gram) and integrity. Distribution coefficients (K_D) for Sb(V) (K_D up to 4600) and Sn(IV) (K_D &lt;0.3) showed good separation (Separation factor of &gt;15,000) of both elements at high concentrations of HCl. Finally, dynamic separations with the DBE resin were capable of recovering up to 79 ± 2 % of radioantimony (^1xxSb(III)) in 2 mL of 0.5 M sodium thioglycolate solution when separating nanogram quantities of ^1xxSb from tens of milligrams of stable tin. Quantitative recovery of Sn was also achieved in just 1.5 mL of concentrated hydrochloric acid, indicating the potential for target recycling of enriched ¹¹⁹Sn required for pre-clinical evaluation of ¹¹⁹Sb.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109022"},"PeriodicalIF":3.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nicotinic acetylcholine receptor imaging with [18F]ASEM for skeletal muscle denervation: A novel assessment for peripheral neuromuscular disorders","authors":"Jae Sung Park ,&nbsp;Jin Hwa Jung ,&nbsp;Seog-Young Kim ,&nbsp;Nare Ko ,&nbsp;Sang Ju Lee ,&nbsp;Seung Jun Oh ,&nbsp;Jin-Sook Ryu ,&nbsp;Da Bin Ko ,&nbsp;Won Kim ,&nbsp;Kyunggon Kim ,&nbsp;Yong-il Kim ,&nbsp;Seung Hak Lee","doi":"10.1016/j.nucmedbio.2025.109023","DOIUrl":"10.1016/j.nucmedbio.2025.109023","url":null,"abstract":"<div><h3>Purpose</h3><div>Despite its invasive and subjective nature, needle electromyography (nEMG) remains a standard method for evaluating peripheral nerve injuries. Increased alpha-7 nicotinic acetylcholine receptor (alpha7-nAChR) expression has been observed in an animal nerve injury model of muscle denervation. Hence, we used [¹⁸F]ASEM positron emission tomography (PET) to investigate the temporal characteristics of alpha7-nAChR expression following skeletal muscle denervation, and tested the correlation between nerve injury severity and [¹⁸F]ASEM PET uptake intensity.</div></div><div><h3>Methods</h3><div>We established a sciatic nerve injury rat model of skeletal muscle denervation. First, [¹⁸F]ASEM PET and nEMG were conducted simultaneously in the complete nerve injury models over time. Next, we used a partial nerve injury model to establish signal intensity as a function of nerve injury severity. Maximum standardized uptake value (SUVmax) and lesion-to-normal ratio (LNR) were used to semi-quantitatively represent [¹⁸F]ASEM uptake.</div></div><div><h3>Results</h3><div>Increased [¹⁸F]ASEM uptake began 1 day after denervation (SUVmax, denervation, 1.00 ± 0.32; SUVmax, control, 0.62 ± 0.23; <em>P</em> &lt; 0.05; <em>n</em> = 7) and lasted to the final 12-week time point. LNR also increased 1 day after denervation, detecting earlier changes compared to nEMG. The signal intensity of [¹⁸F]ASEM uptake in denervated skeletal muscle was significantly associated with nerve injury severity (Spearman correlation coefficient between SUVmax and nerve injury severity = 0.82; Spearman correlation coefficient between LNR and nerve injury severity = 0.75; both <em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>[¹⁸F]ASEM PET targeting the alpha7-nAChR can be used to assess effects of skeletal muscle denervation. This molecular imaging modality holds potential for early assessment of peripheral nerve injury and may also facilitate the evaluation of the injury severity.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109023"},"PeriodicalIF":3.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptation of a commercially available module for the production of alpha-[11C]methyl-L-tryptophan ([11C]AMT) for human use","authors":"Karsten Bamminger ,&nbsp;Cécile Philippe ,&nbsp;Natalie Schindler ,&nbsp;Verena Pichler ,&nbsp;Lukas Nics ,&nbsp;Wolfgang Wadsak ,&nbsp;Andreas Hahn ,&nbsp;Rupert Lanzenberger ,&nbsp;Marcus Hacker ,&nbsp;Chrysoula Vraka","doi":"10.1016/j.nucmedbio.2025.109020","DOIUrl":"10.1016/j.nucmedbio.2025.109020","url":null,"abstract":"<div><div>The complex radiosynthesis of alpha-[¹¹C]methyl-L-tryptophan ([¹¹C]AMT) involves harsh chemicals and conditions, posing challenges for its implementation on commercially available synthesis modules. This study describes the adaptation of the GE TRACERlab FX2 C module for [¹¹C]AMT production using both a half-manual approach and a semi-automated method incorporating a 16-way valve system.</div><div>[¹¹C]AMT was synthesized with decay-corrected radiochemical yields of 13 ± 7.5 % (half-manual) and 10.4 ± 4.1 % (semi-automated), with radiochemical purities exceeding 95 %. The half-manual approach demonstrated higher reliability in synthesis success but required increased operator intervention, while the semi-automated method minimized radiation exposure to the operator. Key factors influencing synthesis success included the preparation and precise addition of lithium diisopropylamide and the use of a soda lime column to mitigate iodine contamination during [¹¹C]CH₃I transfer.</div><div>This work presents a practical and scalable solution for producing [¹¹C]AMT on a commercially available module, enabling its broader application in clinical research, particularly in brain imaging and pediatric oncology.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"146 ","pages":"Article 109020"},"PeriodicalIF":3.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution of [18F]BCPP-BF in humans: a first-in-human positron emission tomography study","authors":"Kengo Sato ,&nbsp;Tomoyasu Bunai ,&nbsp;Akinori Oda ,&nbsp;Hiroyuki Ohba ,&nbsp;Yoshitaka Sano ,&nbsp;Aoi Tokui ,&nbsp;Hideo Tsukada ,&nbsp;Sadahiko Nishizawa ,&nbsp;Norihiro Harada ,&nbsp;Yasuomi Ouchi","doi":"10.1016/j.nucmedbio.2025.109019","DOIUrl":"10.1016/j.nucmedbio.2025.109019","url":null,"abstract":"<div><h3>Introduction</h3><div>[¹⁸F]BCPP-BF and [¹⁸F]BCPP-EF are PET probes used to evaluate mitochondrial function by targeting MC-I. Clinical studies on [¹⁸F]BCPP-EF have been reported, particularly brain studies. However, no reports exist on the use of [¹⁸F]BCPP-BF in humans. Therefore, in this study, we aimed to apply [¹⁸F]BCPP-BF to humans for the first time to assess its safety and radiation dose. We also aimed to explore the whole-body distribution of both probes by comparing the data acquired from the same participants.</div></div><div><h3>Methods</h3><div>Ten healthy participants underwent whole-body PET/CT measurements of [¹⁸F]BCPP-BF (117.0–153.8 MBq/body) for 90 min. Approximately 2–3 weeks after the measurements, the participants underwent [¹⁸F]BCPP-EF (109.2–158.8 MBq/body) measurements. Thirteen volumes of interest (VOIs) were manually drawn on the brain and peripheral organs using PET/CT images to evaluate the distribution and kinetics of the probes. The equivalent dose for each organ and the whole-body effective dose for each participant were calculated according to the Medical Internal Radiation Dose schema using OLINDA/EXM software.</div></div><div><h3>Results</h3><div>The highest radiation doses from the administration of [¹⁸F]BCPP-BF were observed in the small intestine (65.5 ± 8.7 μGy/MBq), and the estimated effective dose (16.3 ± 2.3 μSv/MBq) was well-tolerated. There were no clinically significant safety concerns. A high accumulation of [¹⁸F]BCPP-BF was observed in the kidney, pancreas, and heart, consistent with the findings in previously reported animal studies. The distributions of both tracers were similar. However, the kinetics of [¹⁸F]BCPP-BF were different, with higher uptake and slower washout in the kidney and pancreas, and lower uptake and slower washout in the brain and liver, from those of [¹⁸F]BCPP-EF.</div></div><div><h3>Conclusion</h3><div>[¹⁸F]BCPP-BF is safe and acceptable for clinical use owing to its low toxicity and radiation dose. [¹⁸F]BCPP-BF and [¹⁸F]BCPP-EF generally exhibited similar whole-body distributions; however, their organ-specific kinetics differed slightly. The appropriate selection of these probes can provide a more accurate assessment of human mitochondrial function.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 109019"},"PeriodicalIF":3.6,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Affinity maturation and optimization of CD44v6-targeting antibodies for molecular radiotherapy","authors":"Anja Charlotte Lundgren Mortensen ,&nbsp;Camilla Hofström ,&nbsp;Helena Persson ,&nbsp;Leif Dahllund ,&nbsp;Fredrik Y. Frejd ,&nbsp;Marika Nestor","doi":"10.1016/j.nucmedbio.2025.109012","DOIUrl":"10.1016/j.nucmedbio.2025.109012","url":null,"abstract":"<div><h3>Aim</h3><div>This study aimed to improve the efficacy of the CD44v6-targeting antibody UU-40 for molecular radiotherapy through affinity maturation and IgG subclass optimization.</div></div><div><h3>M&amp;M</h3><div>A panel of affinity-matured antibody candidates was generated and characterized as both human IgG4 and IgG1 with LALA mutations. Surface plasmon resonance and LigandTracer analyses identified several candidates with superior affinity and off-rates compared to the parental UU-40. Biodistribution studies in xenograft models using Lutetium-177 (¹⁷⁷Lu)-labeled antibodies showed improved tumor retention for selected candidates, particularly UU-A-155. Species cross-reactivity assays confirmed binding to cynomolgus and rabbit v6-peptides, supporting future toxicity studies.</div></div><div><h3>Results</h3><div>The IgG1 LALA format demonstrated reduced binding to Fcγ receptors, potentially improving the safety profile. UU-A-155 emerged as the lead candidate for clinical translation, showing superior performance in both affinity and tumor retention. Our findings highlight the importance of comprehensive <em>in vitro</em> and <em>in vivo</em> assessments in antibody development, and provides valuable insights into optimizing antibody-based molecular radiotherapy.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 109012"},"PeriodicalIF":3.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation dosimetry of the 18 kDa translocator protein ligand [18F]PBR111 in humans","authors":"Benjamin B. Tournier ,&nbsp;Zahra Mansouri ,&nbsp;Yazdan Salimi ,&nbsp;Kelly Ceyzériat ,&nbsp;Gregory Mathoux ,&nbsp;Hélène Richard-Lepouriel ,&nbsp;Daniel Zullino ,&nbsp;Frédéric Bois ,&nbsp;Habib Zaidi ,&nbsp;Valentina Garibotto ,&nbsp;Stergios Tsartsalis ,&nbsp;Philippe Millet","doi":"10.1016/j.nucmedbio.2025.109011","DOIUrl":"10.1016/j.nucmedbio.2025.109011","url":null,"abstract":"<div><h3>Purpose</h3><div>The 18 kDa translocator protein (TSPO) is a mitochondrial protein that becomes overexpressed during neuroinflammatory conditions, such as in Alzheimer's disease or multiple sclerosis. TSPO is of interest because it serves as a marker for microglial and astrocytic activity, measurable via in vivo positron emission tomography (PET) molecular imaging. [¹⁸F]PBR111 is a second-generation TSPO PET radioligand with high signal specificity but a sensitivity to TSPO polymorphism, in comparison with first-generation ligands. This study focused on the biodistribution and dosimetry of [¹⁸F]PBR111 in healthy humans.</div></div><div><h3>Method</h3><div>Six volunteers (three males, three females) were administered approximately 200 MBq of [¹⁸F]PBR111. Organs such as the lungs and liver showed the highest initial radioactivity level, while the bone marrow and bladder accumulated activity over time, likely reflecting ligand defluorination and elimination.</div></div><div><h3>Results</h3><div>Dosimetry findings revealed a total effective dose of 16.17 μSv/MBq, equivalent to 3.04 mSv per examination. Compared to animal models, human dosimetry showed lower radiation exposure, highlighting discrepancies in predictive models. Organ-specific dose comparisons with other TSPO ligands ([¹⁸F]PBR06, [¹⁸F]FEPPA, [¹⁸F]FEDAA1106) revealed similar distribution patterns. This study underscores the clinical viability of [¹⁸F]PBR111 for TSPO imaging, providing critical data for optimizing its safe use in research and clinical settings.</div></div><div><h3>Conclusion</h3><div>The findings support its potential for studying neuroinflammatory and systemic diseases. The trial registration number is <span><span>NCT06398392</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 109011"},"PeriodicalIF":3.6,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How green are radiopharmaceutical sciences?","authors":"Verena Pichler ,&nbsp;Matthias Manfred Herth ,&nbsp;Verena Hugenberg ,&nbsp;Peter J.H. Scott ,&nbsp;Sarah Spreckelmeyer ,&nbsp;Sophie Stotz ,&nbsp;Giancarlo Pascali","doi":"10.1016/j.nucmedbio.2025.109010","DOIUrl":"10.1016/j.nucmedbio.2025.109010","url":null,"abstract":"<div><div>The rapid growth of radiopharmaceutical sciences, driven by regulatory approvals of theranostic agents and the expanding role of PET imaging, underscores the need for sustainable and green practices. While radiopharmaceuticals offer high precision and targeted therapy with minimal systemic toxicity, the field faces challenges related to increasing demand, energy consumption, and waste management. The nuclear medicine market is projected to reach $30 billion by 2030, necessitating the integration of sustainability principles such as green chemistry and green engineering into radiopharmaceutical development. Given the energy-intensive nature of radiochemical processes, these principles provide strategies for reducing environmental impact. However, radiopharmaceutical sciences require adaptations to traditional sustainability frameworks due to factors like radiation safety, speed, and automation. This perspective examines the applicability of the 12 principles of green chemistry and engineering, proposing nine key principles tailored to radiopharmaceutical sciences. These principles address waste prevention, radionuclide recycling, energy efficiency, and the adoption of cleaner irradiation technologies. As the field evolves, incorporating sustainability into training programs and research initiatives will be essential.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 109010"},"PeriodicalIF":3.6,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals","authors":"A.R. Jalilian ,&nbsp;J. Kleynhans ,&nbsp;P. Bouziotis ,&nbsp;F. Bruchertseifer ,&nbsp;S. Chakraborty ,&nbsp;E. De Blois ,&nbsp;M. Denecke ,&nbsp;U. Elboga ,&nbsp;M. Gizawy ,&nbsp;C. Horak ,&nbsp;J. Jang ,&nbsp;A. Korde ,&nbsp;A. Majkowska-Pilip ,&nbsp;A. Mdlophane ,&nbsp;B. Ocampo-Garcia ,&nbsp;S.V. Selivanova ,&nbsp;V. Starovoitova ,&nbsp;W. Wojdowska ,&nbsp;J.R. Zeevaart ,&nbsp;V. Radchenko","doi":"10.1016/j.nucmedbio.2025.109008","DOIUrl":"10.1016/j.nucmedbio.2025.109008","url":null,"abstract":"<div><div>Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on ²²⁵Ac-radiopharmaceuticals.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 109008"},"PeriodicalIF":3.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy” [Nucl Med Biol (March–April 2025) 108990]","authors":"Marianna Tosato ,&nbsp;Chiara Favaretto ,&nbsp;Janke Kleynhans ,&nbsp;Andrew R. Burgoyne ,&nbsp;Jean-François Gestin ,&nbsp;Nicholas P. van der Meulen ,&nbsp;Amirreza Jalilian ,&nbsp;Ulli Köster ,&nbsp;Mattia Asti ,&nbsp;Valery Radchenko","doi":"10.1016/j.nucmedbio.2025.109009","DOIUrl":"10.1016/j.nucmedbio.2025.109009","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"142 ","pages":"Article 109009"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143636718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}